ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FibroGenesis Announces the Filing of its 250th Patent for Fibroblast Cell Therapy Platform
November 13, 2020FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), announced the filing of its 250th patent related to its fibroblast cell therapy platform. -
FibroGenesis Files Expanded Patent Coverage for Fibroblast Cell Therapy for COVID-19 ARDS
April 02, 2020FibroGenesis announced the filing of United States Provisional Patent Number 63/002,134 titled, "Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus."
Pharma Sources Insight January 2025
